Business
Corvus Presents New Data on its Investigational ITK Inhibitor CPI-818 at the American Society of Hematology (ASH) Annual Meeting & Exposition
Updated interim data from CPI-818’s phase 1/1b clinical trial provide evidence supporting its potential as a treatment for T cell lymphomas New pre-clinical
About this update from Corvus Pharmaceuticals, Inc.
[{"type":"text","content":"Updated interim data from CPI-818’s phase 1/1b clinical trial provide evidence supporting its potential as a treatment for T cell lymphomas New pre-clinical data provide evidence of CPI-818 potential as a treatment for autoimmune lymphoproliferative syndrome (ALPS) BURLINGAME, Calif., Dec. 06, 2020 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that new data on CPI-818, the Company’s ITK inhibitor, were presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, which is taking place as an all-virtual event from December 5-8, 2020. The data include a poster presentation covering updated data from the Phase 1/1b clinical trial for T cell lymphoma and an oral presentation covering pre-clinical data demonstrating its potential for the treatment of autoimmune lymphoproliferative syndrome (ALPS), a rare genetic disease. “The CPI-818 data presented at ASH continue to show encouraging anti-tumor activity and also extend its potential for the treatment of auto-immune disorders,” said Richard A. Miller, M.D., president and chief executive officer of Corvus. “Our Phase 1/1b trial in T cell lymphomas has identified a dose of CPI-818 that was well tolerated, covalently inhibited ITK and demonstrated tumor responses in very advanced, refractory, difficult to treat T cell malignancies. We are also excited by the pre-clinical data in ALPS, which we believe suggests that ITK inhibition may provide a treatment option for this rare genetic disease as well as other T cell mediated autoimmune disorders. We plan to continue studying CPI-818 for these indications in the coming year, including working with our partner Angel Pharmaceuticals in China, given the higher incidence of T cell lymphomas in Asia.” CPI-818 is an investigational, orally bioavailable, covalent inhibitor of ITK designed to have low nanomolar affinity. In vitro studies have shown that it potently inhibited T cell receptor signal transduction. The CPI-818 presentations at ASH are outlined below and can be found on the Corvus website on the publications and presentations page. CPI-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma (Abstract #2068) CPI-818 is currently being studied in a Phase 1/1b clinical t...